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ABSTRACT
Patient- reported outcomes (PROs) are important tools 
in patient- centred medicine and allow for individual 
assessment of symptom burden and aspects of patients’ 
quality of life. While sex and gender differences have 
emerged in preclinical and clinical medicine, these 
differences are not adequately represented in the 
development and use of patient- reported outcome 
measures. However, even in personalised approaches, 
undesirable biases may occur when samples are 
unbalanced for certain characteristics, such as sex or 
gender. This review summarises the current status of the 
literature and trends in PROs with a focus on sex and 
gender aspects.
BACKGROUND
There is an increasing interest in research 
about the influence of sex and gender on 
health in general. Differences in gender 
identity and biological sex are postulated to 
impact the course and perception of a disease 
trajectory and eventually influence diagnosis 
and treatment.1 Both sex (defined by the 
biological underlying genetics) and gender (a 
person’s psychological sense of their identity) 
may therefore influence prevalence, onset, 
trajectory, treatment response and prognosis 
in cancer.2 There is also growing evidence for 
sex and gender having an impact on outcome 
differences in cardiovascular, neurological 
and autoimmune diseases, including disease 
course and treatment response. Yet, there are 
no mandatory requirements to investigate the 
impact of sex and gender on drug receptivity 
or adverse effects in clinical study design. Also 
in preclinical studies and drug development, 
it is common protocol to use animals of one 
sex only. In clinical studies, due to anticipated 
risks of pregnancy or hormonal imbalance, 
women are frequently under- represented, 
which translates into biased interpretation of 
results and pharmacokinetics.3 Yet, sex- related 
factors, as hormonal regulation, and gender- 
related factors, as behavioural differences in 
stress perception, lifestyle and risk- seeking 
behaviour, appear to be relevant influencers 
of disease perception and outcome. Recent 
publications additionally discuss interrelation 
between sex and gender, postulating gender- 
triggered epigenetic effects to modulate the 
expression of biological sex.4 Eventually, 
differences arising from sex and gender gaps 
may lead to a differential use of medical 
services, insufficient treatment of symptoms 
or greater toxicity of medication.5 6 To date, 
there is still little knowledge about the influ-
ence of the overall gender spectrum in medi-
cine, which includes transgender, non- binary 
and genderqueer (TNBGQ) persons. Due to 
sparse publications on TNBGQ and outcome 
studies, this review will mainly focus on the 
female- male dichotomy for patient- reported 
outcomes (PROs). The influence of gender 
on the diseases examined here will however 
be discussed.
The understanding of patients’ symptoms 
in the course of any disease is crucial for 
patient- centred medicine. However, some 
symptoms are often under- reported by the 
patient and may also be underestimated by 
physicians, leading to undertreatment of 
patients.7 One potential cause for underesti-
mated symptoms is the lack of time for deeper 
discussions or the inability to address psycho-
logical symptoms, which are often considered 
more complex than pharmacologically treat-
able physical symptoms.8 Addressing symp-
toms actively and in a structured manner can 
help patients reporting subjective burden. 
Likewise, to monitor the symptom load and 
response to treatment in the course of a 
disease, systematic assessments are useful and 
help to evaluate psychological or physical 
symptoms, as well as the subjective burden of 
the patient.
PROs reflect the patient’s subjective view 
on symptoms, quality of life and burden and 
therefore allow for patient- centred and indi-
vidualised management. They are captured 
by patient- reported outcome measures 
(PROMs), covering several areas of poten-
tial symptoms in the course of a disease. 
Most importantly, emotional burden can be 
covered, including sensitive symptoms that 
patients might not wish to address actively 
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in daily medical routine. Allowing a patient to express 
symptoms that are most relevant to him/her is therefore 
important, and open questions may represent a good 
start to an assessment dialogue with the patient. However, 
a standardised format is more consistent at actively 
inquiring about a broad range of symptoms and other 
aspects of disease burden. Often, patients experience 
more symptoms than they state.9
PATIENT-REPORTED OUTCOME MEASURES
Many validated assessment tools are available and have 
been used recently in routine clinical practice and clinical 
studies, especially in the field of oncology. They mainly 
address symptoms and symptom burden, functional 
status, health- related quality of life (HRQoL), health 
behaviours and patients’ healthcare experience. The 
term ‘quality of life’ has not yet been well defined and is 
commonly used as umbrella term to describe a person’s 
individual perception of well- being, including phys-
ical but also emotional and social aspects of life.10 This 
concept has become an important focus in healthcare 
and has become a frequently assessed endpoint in clin-
ical studies, captured by PROMs. Since patient- reported 
symptoms are intrinsically subjective, it is crucial to use 
the same validated tool for longitudinal assessments in 
order to reduce the chances of bias occurring between 
timepoints of data collection. Table 1 summarises charac-
teristics of some of the most important PROMs in clinical 
medicine.
Given the documented effects of sex and gender on 
health and drug management, it is necessary to explore 
further the influence of sex and gender on PROs, mirroring 
symptom perception and reporting. The existence of sex- 
specific/gender- specific questionnaires covering gynae-
cological or andrological diseases is obvious, but sex and 
gender differences in PRO from other common diseases 
have been under- researched. To date, most guidelines of 
PROM assessments do not take into consideration that 
sex and gender differences can arise as an undesirable 
bias and might influence the results and interpretation of 
the collected information.11 The purpose of the present 
review is to evaluate the current status of sex- specific and 
gender- specific outcome differences in PROs. For this 
review, we conducted a PubMed literature search of all 
relevant studies published through June 2020 using any 
of the following key words: PROs, sex/gender differ-
ences, symptom assessment, symptom severity, pain, 
nausea, vomiting, functional status, fatigue, depression 
sleep, HRQoL, functional status, health behaviours, and 
patient experience, cancer diseases, non- cancer diseases.
PROS IN ONCOLOGY
Cancer, as well as anticancer therapy, can result in 
impaired quality of life, increased symptom load and/
or psychosocial burden. Advocates within oncology have 
called for the systematic use of PROMs to detect prob-
lems that are assessed directly by the patient.12 Although 
often not investigated as primary objective, publications 
of PROM assessments in oncology did assess sex as a 
main variable, and the European Society for Medical 
Oncology (ESMO) recently published a consensus paper, 
confirming a universal male predominance for most 
cancers, and advocating for specific attention to sex and 
gender medicine in oncological practice with the aim 
to optimise treatment for patients.13 Sex- specific cancer 
biology plays a crucial role in the development but also 
the treatment responses in cancer. Y- chromosome- located 
oncogenes or hormonal growth influence may contribute 
to differential cancer disposition.14 15 On the contrary, 
gender aspects have been identified as contributors to 
higher cancer risks, as alcohol consumption and smoking 
habits.16 Overall, gender constructs and biological sex 
both influence disease development. Yet, perception of 
disease and symptoms are relevant factors to diagnosis 
and treatment as well and might be captured differently 
in PROM based on sex and gender. Several studies with 
comparative subgroup analyses found worse self- reported 
outcomes in PRO for female patients with regard to 
symptom burden and perception, despite surviving 
longer than male. A large, population- based analysis 
of PROM- assessed symptoms in patients with oesoph-
ageal cancer under curative treatment, which used 
the Edmonton Symptom Assessment System (ESAS),17 
revealed an overall high symptom burden with severe 
symptoms in up to 50% of patients for anorexia, tiredness 
and overall poor well- being. Among the characteristics 
associated with symptom severity, female sex was consist-
ently present.18 In a study of 120 patients with colorectal 
cancer that completed PROMs for symptom burden, the 
severity score for worrying and lack of energy was signifi-
cantly higher in women compared with men.19 Similarly, 
in a cohort of more than 400 patients with melanoma, 
female patients reported significantly more anxiety over a 
2- year prospective follow- up assessment period compared 
with male patients.20 In a population of patients with 
advanced cancer, including lung, pancreatic or oesopha-
geal tumours, male sex predicted a better emotional well- 
being, assessed by the Functional Assessment of Cancer 
Therapy questionnaire (FACT- G).21 22 In another cohort 
of mixed cancer patients with terminal disease, however, 
symptom burden for pain perception was significantly 
correlated with male gender.23 In brain tumours, the 
sequelae lead to a broad spectrum of complex central 
symptoms, including neurocognitive impairment, 
personality change and motor issues. All of these prob-
lems can have a great impact on HRQoL and activities 
of daily living, as well as devastating social and economic 
consequences. This indicates that the assessment of PROs 
is especially important in order to address all needs 
experienced by patients with brain tumour. In a system-
atic review of 10 studies, all using HRQoL outcomes for 
supportive care interventions in a wide array of different 
tumour types,24 the majority of participants was male, 
with the exception of 3 studies.25–27 Likewise, a large 



















































Table 1 PROMs in medicine (selection)
PROMs Items (N) Subscales Disease
Global HRQoL
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(disease- specific modules 
available)
Edmonton Symptom Assessment System (ESAS) 10 items Pan- cancer




















NCCN Distress Thermometer (DTherm) 1 item Psychological distress (11- point Likert scale) Adult cancer patients
Functional Assessment of Cancer Therapy- Fatigue 
(FACIT- F)
  



































































PROMs Items (N) Subscales Disease
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Functional status   
Karnofsky Performance Status Performance status scale Index 1–5 Adult cancer patients
Functional Assessment of Cancer Therapy- 
cognitive function (FACT- COG)
37 items Perceived cognitive impairments Perceived 
























    
Health behaviours   
Morisky Medication Adherence Scale 8 items Medication taking behaviour Adult cancer patients
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with 5217 patients assessing the added value of HRQoL 
as prognostic marker for overall survival and progression- 
free survival demonstrated that the majority of included 
patients overall were male (61 %),28 pointing towards an 
imbalance of sex. Importantly, in studies that did stratify 
for gender and sex differences, outcome differences by 
sex emerged, often with a worse outcome for female 
patients. In a recent Swedish study, female patients with 
lower grade glioma were reported to have a worse perfor-
mance status preoperatively, which resulted in a delayed 
diagnostic work- up.29 On therapeutic levels, toxicity of 
the alkylating chemotherapy with temozolomide—al-
though administered body surface adapted—was consist-
ently reported to be higher in female patients.30 31 Inter-
estingly, altered body image perception in patients with 
primary brain tumour did not differ by sex,32 whereas in 
a non- brain tumour study, changes of body image were 
seen to have a larger emotional impact on female patients 
compared with male patients.33 Overall, most PROs 
published in cancer did not stratify for sex, despite its 
well- known role as genetic and hormonal disease modi-
fier, contributing to an imbalance in these assessments. 
Subgroup analyses for sex however confirm a differential 
outcome in symptom perception and ultimately outcome 
and treatment. Gender, as factor influencing social roles 
among others, was not in the focus of the analysed publi-
cations, despite being a variable that influences not only 
patient’s behaviour and response to the diagnosis but 
eventually the interpretation of PROs by the clinicians.
Non-cancer diseases
Although PROs have emerged mainly in routine clinical 
practice and clinical trials in oncology, there are several 
non- oncological diseases for which PROs are used. Espe-
cially in the cardiovascular disease spectrum, several 
studies have assessed sex on the one hand and gender 
on the other hand as outcome variable. In heart diseases, 
sex- related influencing factors, as hormonal oestrogen 
protection, have been described.34 Despite this protec-
tive variable, women with ischaemic heart disease are 
more often underdiagnosed and less likely to receive 
classic treatment.35 36 Moreover, the risk for recurrence 
of ischaemic heart disease eventually increases in patients 
with feminine personality traits and is independent of the 
female sex,37 distinctly pointing towards a gender bias. 
Finally, the sex of the physician eventually is an influ-
encing factor as well. Mortality rates of female patients 
with myocardial infarction increase when treated by 
male physicians compared with female physicians.38 With 
regard to PROs, data on sex and gender aspects is less 
available. Despite a lower age- adjusted incidence of stroke 
in women, female patients who had a stroke usually expe-
rience a worse outcome with regard to HRQoL, activity 
limitations or depression compared with male patients 
who had a stroke.39–41 In studies specifically designed to 
assess patient- reported HRQoL by sex, women showed a 
worse outcome in activities of daily living, assessed by the 
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In another study using the European Quality of Life-5 
Dimensions (EQ- 5D) instrument in more than 1000 
patients who had a stroke, women scored a significantly 
lower quality of life at 3 months and 12 months post-
stroke.43
Similarly, in cardiovascular assessments, compara-
tive PROMs for patients with atrial fibrillation showed 
a sex/gender imbalance with women reporting more 
severe perception of symptoms, poorer quality of life 
and increased symptoms of anxiety and depression.44 
While one can postulate that physical and psychological 
symptoms are intertwined in this cardiac population, the 
reasons for the sex/gender imbalance demonstrated in 
this study remained unclear.
PROs in palliative care
PROs are appreciated tools in palliative care, where 
patient- centered outcome shifts even more in the focus 
and symptom burden is assessed in a population with a 
broad variety of primary diseases. Sex and gender aspects 
are usually not in the focus of PRO assessments. In a 
register- based study of patients with cancer referred to 
palliative care who completed the European Organisation 
for Research and Treatment of Cancer (EORTC)- QLQ- 
C15- PAL, associations with symptoms and sex showed 
increased risk of nausea for women, whereas other symp-
toms, such as pain or sleeplessness, showed a stronger asso-
ciation with age than sex.45 In contrast, a secondary anal-
ysis of an RCT including 350 patients suffering from lung 
or gastrointestinal cancers and receiving early palliative 
care reported better quality of life and lower depression 
scores in self- reported assessments of male patients with 
lung cancer.46 Conversely, male patients with advanced 
cancer reported dyspnoea more frequently47 48 and 
greater severity of dyspnoea relative to female patients.49 
Results regarding fatigue in palliative care patients have 
been inconsistent with some studies reporting higher 
fatigue in female palliative care patients50 51 and other 
studies documenting lower levels of fatigue in females52 
relative to male palliative care patients. The same study 
found terminally ill female patients with cancer to be in a 
more positive mood compared with male patients of the 
same cohort. Interestingly, when comparing symptom 
distress between male and female palliative care patients, 
female patients reported higher levels of distress related 
to pain, nausea and fatigue relative to their male counter-
parts.53 The same study found that females had to report 
higher levels of distress in order to receive adequate pain 
treatment.
Caregiver-reported outcomes
In a study of caregivers of palliative care patients, taking 
care of a loved one is associated with high distress due 
to the patient’s progressive health deterioration, antic-
ipatory grief about the inevitable death, adoption of 
supportive responsibilities, financial stressors and disrup-
tion of the caregiver’s social and personal life.54 During 
the illness trajectory, caregivers frequently experience 
pain, fatigue, sleep disturbances and depression.55–57 
Although gender roles are changing and an increasing 
number of men are assuming caregiving roles, caregiving 
responsibilities still disproportionately affect women.58 
Women assisted with more personal care were involved 
in more caregiving tasks and provided more caregiving 
hours than men.59 However, while earlier studies iden-
tified poorer health outcomes for female caregivers, 
including increased psychological distress and physical 
health problems,60 61 results from more recent studies 
indicate a decline of this gender difference in caregiving 
variables.59 It is assumed that female and male caregivers 
all experience grief, distress and depression.62 Corre-
spondingly, the retrospective assessment of psychosocial 
outcomes by gender most commonly found no signifi-
cant influence of gender on outcome scores when specif-
ically assessed.63–65 However, in studies demonstrating a 
gender- shifted outcome, female gender was associated 
with a higher level of distress.66 67 A postulated explana-
tion included perception of insufficient caring and self- 
efficacy in female carers.68 Women relative to men are 
at greater risk for experiencing emotional burdens of 
caregiving.69 One possible explanation for this consistent 
finding is that women often assume the responsibilities of 
full- time employment simultaneously with child- rearing 
and household maintenance. Thus, the risk of competing 
responsibilities is greater in women than in men, which 
can result in a sense of being ‘entrapped in informal 
care’.63 70 Yet, in caregivers of children with cancer, no 
differences were found between paternal or maternal 
proxy scorings with regard to distress, indicating that 
gender in this context is not of major importance.71 
Overall, although sex and gender are not always well 
separable, self- reported outcome measures in caregivers 
are more often determined by gender aspects and behav-
ioural characteristics.
Table 2 lists publications that included PROs by sex/
gender (not exhaustive).
DISCUSSION
Although sex and gender differences in disease prev-
alence, treatment tolerability and overall treatment 
outcomes have been reported increasingly in the last 
years, information on sex- specific and gender- specific 
aspects in PROMs has remained sparse.
In this review, we found that, although often not inves-
tigated as primary objective, most studies evaluating 
PROMs in oncological and non- oncological diseases 
have assessed sex as a main variable. Informations on 
gender are often lacking, although several reports 
include gender as a synonym term for sex when strati-
fying globally for a male- female dichotomy. Evaluating 
PROs for sex and gender differences displays consis-
tent evidence that women and men report differently 
their physical symptoms, HRQoL and psychosocial 
burden. Most studies found sex/gender differences for 



















































Table 2 PRO by sex and gender
Reference Publication PRO measure Outcomes
Appelros et al39 A review on sex differences in stroke treatment 
and outcome
– Post- stroke depression and low quality of life seem to be more 
common among women.
Armstrong et al30 Risk analysis of severe myelotoxicity with 
temozolomide: the effects of clinical and 
genetic factors
– Risk of developing myelotoxicity ranged from 0% to 33% (male) and 
from 0% to 100% (females).
Bushnell et al43 Sex differences in quality of life after ischaemic 
stroke
European Quality of Life-5 
Dimensions (EQ- 5D)
Women have worse QoL than men up to 12 months after stroke, 
even after adjusting for important sociodemographic variables, 
stroke severity and disability.
Carey and Posavac52 Holistic care in a cancer care centre Profile of Moods States (POMS) Women reported a better and more positive mood compared with 
male patients and scored lower anxiety and fatigue.
Carstam et al29 Socioeconomic factors affect treatment 
delivery for patients with low grade glioma: a 
Swedish population- based study
– Female sex, low income and low education showed worse 
preoperative performance status.
Falk et al53 Differences in symptom distress based on 
gender and palliative care designation among 
hospitalised patients
Edmonton Symptom Assessment 
Scale (ESAS)
Females reported higher levels of symptom distress than males 
related to pain, fatigue and nausea. When comparing symptom 
distress between males and females with documentation pertaining 
to symptoms, there were significant differences implying that females 
had to report higher levels of symptom distress than males in order 
to have their symptoms documented.
Gargano and Reeves42 Sex differences in stroke recovery and stroke- 
specific quality of life: results from a statewide 
stroke registry
Barthel Index
Stroke- Specific Quality of Life 
Questionnaire
Compared with males, female stroke survivors had lower functional 
recovery and poorer quality of life 3 months postdischarge. These 
differences were not explained by females' greater age at stroke 
onset or other demographic or clinical characteristics.
Gleason et al44 Association of sex and atrial fibrillation 
therapies with patient- reported outcomes
Atrial Fibrillation Effect on QualiTy of 
Life (AFEQT)
Patient- Reported Outcome 
Measurement Information System-29 
(PROMIS)
Women were more likely to report poorer functional status (−2.63, 
95% CI −3.86 to –1.40) and poorer aF- related quality of life, higher 
anxiety (2.33, 95% CI 1.07 to 3.59), higher symptoms of depression 
(1.48, 95% CI 0.31 to 2.65) and aF symptom severity (0.29, 95% CI 
0.07 to 0.52).
Gupta et al18 Patient- reported symptoms for oesophageal 
cancer patients undergoing curative intent 
treatment
Edmonton Symptom Assessment 
System (ESAS)
Characteristics associated with severe scores for all symptoms 
included female sex, high comorbidity, lower socioeconomic status, 
urban residence and symptom assessment temporally close to 
diagnosis.
Hansen et al45 Age, cancer site and gender associations 
with symptoms and problems in specialised 
palliative care: a large, nationwide, register- 
based study
EORTC- QLQ- C15- PAL Gender, age and cancer diagnosis were significantly associated with 
most symptoms/problems. The strongest associations between 
symptoms/problems and gender and age, respectively, were 
increased risk of nausea in women, as well as increased risk of poor 
physical function and reduced risk of sleeplessness and pain with 
increasing age.
Kanbayashi et al23 Statistical validation of the relationships of 
cancer pain relief with various factors using 
ordered logistic regression analysis






















































Reference Publication PRO measure Outcomes
Matthews et al69 Family caregivers and indicators of cancer- 
related distress
Quality of Life- Family Tool (QOL- F) Female sex, less practice of healthy behaviours, greater number of 
patient care needs and pessimistic expectations (all ps <0.05) also 
were significant predictors for distress and emotional burden.
Mercadante et al49 The course of symptom frequency and 
intensity in advanced cancer patients followed 
at home
Karnofsky Performance Score Dyspnoea was more severe in males at K50 (p<0.008).
Nipp et al46 Differential effects of early palliative care 
based on the age and sex of patients 
with advanced cancer from a randomised 
controlled trial
Functional Assessment of Cancer 
Therapy- General (FACT- G)
Patient Health Questionnaire 9 (PHQ-
9)
Male patients with lung cancer assigned to EPC reported better QoL 
(FACT- G: B=9.31; p=0.01) and lower depression scores (PHQ-9: 
B=−2.82; p=0.02), but the effects of EPC on these outcomes were 
not significant for female patients.
Pottie et al62 Informal caregiving of hospice patients – Caregiver characteristics (ie, ethnicity, gender, age, relationship with 
patient) were not found to be associated with caregiver outcomes.
Röhrl et al19 Symptoms during chemotherapy in colorectal 
cancer patients
Memorial Symptom Assessment 
Scale (MSAS)
Karnofsky Performance Status (KPS)
Age, sex, educational level, performance status, treatment intent and 
type of chemotherapy were significantly associated with symptom 
severity throughout the chemotherapy trajectory.
Zeng et al50 Fatigue in advanced cancer patients attending 
an outpatient palliative radiotherapy clinic 
as screened by the Edmonton Symptom 
Assessment System
Karnofsky Performance Score A low KPS (p<0.0001), being female (p=0.0056), or being referred 
for bone metastases (p=0.0185) significantly correlated with higher 
levels of fatigue.
Zimmermann et al51 Predictors of symptom severity and response 
in patients with metastatic cancer
Edmonton Symptom Assessment 
Scale (ESAS)
Symptom improvement was independently predicted by worse 
baseline EDS score and female gender.
Zimmermann et al22 Determinants of quality of life in patients with 
advanced cancer
Functional Assessment of Cancer 
Therapy- General (FACT- G)
Functional Assessment of Chronic 
Illness Therapy–Spiritual Well- being 
(FACIT- Sp)
Male patients reported better emotional well- being.
aF, atrial fibrillation; EDS, ESAS distress score; EORTC- QLQ, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; EPC, early palliative care; 
PRO, patient- reported outcome.
Table 2 Continued
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nausea, dyspnoea or pain, and for psychological symp-
toms, such as anxiety and mood. Often, the outcomes 
in female patients were worse compared with male. Sex 
differences in human physiology as well as the fact that 
women are often under- represented in clinical trials as 
discussed above may explain why women report more 
adverse events to medication compared with men.72 For 
instance, previous studies have postulated different pain 
thresholds between genders.73 On the contrary, a meta- 
analysis of studies analysing the use and response of men 
and women to opioids for pain control found evidence 
that sex did not affect response to opioids 30 min after 
application, but that women self- administered lower 
daily doses of opioids.74 Another perspective recognises 
the multimodal perception of pain, acknowledging 
that pain is sustained not only by physical but also by 
emotional burden. It follows that outcomes may vary 
depending on the proposed and accepted treatment 
options, including psychological and spiritual care.75 
Finally, the role of the assessing person, physician or 
nurse should not be underestimated either. Sex or 
gender of the diagnostician can influence the outcome 
of a disease, as for women with cardiac infarction 
described to have higher mortality rates when treated 
by male doctors.38 Likewise, the perception of the sex/
gender of the patient by the physician can influence 
a diagnostic assessment as well. Male patients with 
depressive disorders seeking treatment are less likely to 
be diagnosed with major depression, even with similar 
assessment scores as female comparators.76 Therefore, 
several factors may influence differential symptom 
perception and therefore reported outcomes between 
sexes and genders. Either way, treatment based on 
unbalanced studies can eventually lead to insufficient 
or excessive medication or treatment in general. Yet, 
most guidelines for treatment of diseases are identical 
for men and women. Evaluating whether sex- specific 
treatment modifications can improve outcome should 
be in the focus of future studies.
Limitations of this study arise from the fact that 
gender differences were not the primary endpoint in 
most reviewed publications and that both PROM tools 
and investigated patient populations were hetero-
geneous. While there is an increasing number in 
publications assessing epidemiological, diagnostic or 
therapeutic differences for sex and gender nowadays, 
the role of gender bias in outcome measures reported 
by patients themselves is under- investigated to date. 
Furthermore, data beyond the binary gender spectrum 
is missing in the current literature as well. These limita-
tions underline the need to consider prospective collec-
tion of gender- specific aspects in PROs in comparable, 
balanced patient populations. Correspondingly, algo-
rithms for clinical trials and routine clinical practice 
should include assessments validated for gender or sex 
differences.
Recently, normative data for the general population 
in Europe, Canada and the USA has been assembled by 
means of EORTC- QLQ- C30 collection77 and stratified by 
sex. Here, men reported better scores for overall quality 
of life and emotional function compared with women, 
which was also observed in other norm data studies,78 79 
confirming sex and gender differences beyond disease. 
Hence, the collection of normative data might repre-
sent an important step towards a better understanding 
of gender and sex influence in PROs. Other approaches 
that might be helpful include the use of tools that help 
with the design of studies, incorporating sex and gender 
questions with possible impact on results, assisting in 
identifying undesirable biases due to gender imbal-
ances and pointing out desirable biases that would 
help with targeted treatment for each gender.11 80 In 
patient- centred care with appropriate, focused reaction 
to patient- reported symptoms and symptom burden, it 
is warranted to include further differential assessments 
by gender. Physicians and medical personnel should be 
aware of sex and gender differences not only in phar-
macokinetics or disease trajectories but also on the level 
of symptom perception.
CONCLUSION
In the process of development and validation of 
PROMs, it is crucial to have a well- balanced population 
of the gender spectrum, assessing differences between 
male and female reports and including gender identi-
ties beyond the binary concept. When PROMs are used 
in clinical practice, comparative analyses between the 
groups should be included early in order to detect 
potential gender- specific outcome differences.
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